SCHEMBL2065621

SCHEMBL2065621

CCN(CC)Cc1sc(-c2nc(-c3ccc(O)cc3OC)no2)cc1C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 8/20 0.40
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
GUSB P08236 6/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 3/20 0.37
MAPT P10636 3/20 0.37
S1PR3 Q99500 2/20 0.37
HTT P42858 2/20 0.37
HSD17B10 Q99714 2/20 0.37
TSHR P16473 1/20 0.37
ALDH1A1 P00352 2/20 0.36
TP53 P04637 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2064752 0.82 S1PR1 (0.43) S1PR1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL2065671 0.81 S1PR1 (0.44) S1PR1NPC1RAB9ASMN1; SMN2S1PR3
SCHEMBL2064249 0.74 S1PR1 (0.47) S1PR1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2064223 0.73 RARA (0.59) S1PR1S1PR3
SCHEMBL2064853 0.73 RARA (0.46) S1PR1SMN1; SMN2MAPTS1PR3HTT
SCHEMBL2064625 0.73 S1PR1 (0.43) S1PR1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL2064319 0.73 S1PR1 (0.48) S1PR1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2065272 0.73 S1PR1 (0.51) S1PR1S1PR3
SCHEMBL3721244 0.73 S1PR1 (0.43) S1PR1S1PR3
SCHEMBL2064028 0.72 S1PR1 (0.56) S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222667-B1 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2013-02-20 EP disclosed
US-8148410-B2 Thiophene derivatives as agonists of S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2012-04-03 US disclosed
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2010-10-14 US disclosed
EP-2222667-A2 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 Actelion Pharmaceuticals Ltd. (CH) 2010-09-01 EP disclosed
WO-2009074950-A2 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 S1PR1, S1PR3, S1PR5 S1PR1 1/4885CA2 4646/4885CA9 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.